Tag: MMAF
Advances in the Development of Dual-Drug Antibody Drug Conjugates
Antibody drug conjugates (ADCs) are touted for their ability to site selectively deliver a small molecule chemotherapeutic directly to a tumor cell, bypassing off target side effects from systemic circulation. To date, eleven ADCs have been FDA approved in the United States and >200 more in the clinical pipeline (clinicaltrials.gov).
Depatuxizumab Mafodotin Did Not Demonstrate Survival Benefit in INTELLANCE-1 Study
Depatuxizumab mafodotin (also known as Depatux-M, and previously known as ABT-414), an antibody-drug conjugate (ADC) being developed by AbbVie, did not demonstrate a survival...
Four Ways to Show Nonobviousness of ADC Inventions
As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.
ADCs – The Dawn of a New Era?
Two decades ago, ADCs were hailed as a major breakthrough, especially in the area of oncology therapeutics. The concept of delivering a potent drug payload directly to the site of the tumor for maximum effect with minimal damage caused to non-cancerous cells was viewed as, if not the Holy Grail of cancer treatment, at least a significant advance towards precision medicine. However, the concept has proved difficult to translate into clinical success.
Denintuzumab Mafodotin: Testing Novel Regimens for Frontline and Relapsed DLBCL
Highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A; Seattle Genetics) in B-cell malignancies, including diffuse large B-cell lymphoma, also known as DLBCL, and B-lineage...
Phase II Trial of Denintuzumab Mafodotin Combination Therapy in Relapsed or...
A randomized phase II clinical trial of denintuzumab mafodotin, also known as SGN-CD19A (SGN-19A), in combination with the second-line salvage regimen of rituximab (Rituxan®;...
Novel IgM-derived Antibody-drug Conjugate Targets Fcμ-receptor in Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia or CLL, one of the most common forms of leukemia in Europe and North America, is a disorder of morphologically mature...
Ongoing Phase I Clinical Trial of SGN-CD19A Demonstrates Encouraging Activity and...
Phase I interim data from a clinical trial with SGN-CD19A being developed for the treatment of B-cell malignancies, including acute lymphoblastic leukemia or ALL -- shows...
Pfizer and Seattle Genetics Agree on Antibody-Drug Conjugate Collaboration
Pfizer and Seattle Genetics, a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer ,...
